Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer.

ABSTRACT:

Purpose

We aimed to characterize the genomic landscape of hormone receptor-positive (HR+)/HER2-negative breast cancer in patients with hormone therapy-resistant and -sensitive phenotypes.

Methods

HR+/HER2-negative patients who were disease-free for ≥2 years were considered hormone therapy-sensitive (n = 19), while those who experienced disease progression within 2 years were considered hormone therapy-resistant (n = 48). Whole-exome sequencing (WES) was performed on paired (treatment-naïve and relapse-site) tumor and germline-derived DNA from resistant patients (n = 19), and targeted next-generation sequencing (NGS) was performed on plasma-derived circulating tumor DNA (ctDNA) from resistant (n = 35) and sensitive (n = 19) patients.

Results

In 19 resistant patients, t

SUBMITTER: Chaubal R 

PROVIDER: S-EPMC12331804 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature